This article is more than 5 years old. Information may no longer be current.
MacuLogix adds $38.7 million in Series D financing
Click Here to Manage Email Alerts
MacuLogix has completed $38.7 million in Series D financing led by Vivo Capital, according to a press release.
The funds will be used to expand the company’s infrastructure in order to support the sales and practice integration of the AdaptDx automated dark adaptometer, which assists providers in detecting, monitoring and treating age-related macular degeneration, the release said.
“AMD is the leading cause of adult blindness in the Western world because we haven’t had the technology or tools to effectively detect and manage this progressive, chronic disease — until now. Our company is determined to see AdaptDx functional testing become the standard of care, enabling eye care professionals to detect, treat and manage AMD earlier and more effectively,” William D. McPhee, president and CEO of MacuLogix, said in the release. “With this funding and the addition of Vivo Capital, we are fully backed by a strategic group of investors who support our company’s vision to eliminate blindness caused by AMD.”
Other investors include Fisk Ventures, Roche Venture Fund, Berwind Private Equity and Life Sciences Greenhouse of Central Pennsylvania, and this round of funding brings MacuLogix’s venture funding total to $51 million.
With this round of funding ,Vivo Capital Managing Director Jack B. Nielsen and Vivo Capital Principal Nathan Dau, as well as Head of Roche Venture Fund Carole Nuechterlein, will join the MacuLogix board of directors.